A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.
about
Adjuvant therapy for resected pancreatic cancerChemoradiotherapy for locally advanced pancreatic cancer patients: is it still an open question?Adjuvant therapy for pancreas cancer in an era of value based cancer careNovel agents for advanced pancreatic cancerAlbumin-bound paclitaxel in solid tumors: clinical development and future directionsNovel adjuvant therapies for pancreatic adenocarcinomaAdvances in chemotherapy for pancreatic cancerIncreased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trialsPhase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.Stem cell Transplantation for Eradication of Minimal PAncreatic Cancer persisting after surgical Excision (STEM PACE Trial, ISRCTN47877138): study protocol for a phase II study.The addition of radiation to chemotherapy does not improve outcome when compared to chemotherapy in the treatment of resected pancreas cancer: the results of a single-institution experienceSequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis.Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma.Neoadjuvant therapy in pancreatic cancer: an emerging strategyAdjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.Current and emerging therapies for the treatment of pancreatic cancer.Adjuvant therapy in pancreatic cancer.Diagnosis and prognostication of ductal adenocarcinomas of the pancreas based on genome-wide DNA methylation profiling by bacterial artificial chromosome array-based methylated CpG island amplification.S-1 in the treatment of pancreatic cancer.Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.Use of a novel herbal medicine in a 75-year-old woman with multi-metastatic pancreatic cancer: A case report and review of the literature.Early recurrence of pancreatic cancer after resection and during adjuvant chemotherapy.Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma.Pancreatic Cancer: Current Options for Diagnosis, Staging and Therapeutic ManagementEarly versus delayed initiation of adjuvant treatment for pancreatic cancerPreoperative Biliary Drainage in Cases of Borderline Resectable Pancreatic Cancer Treated with Neoadjuvant Chemotherapy and Surgery.Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of lifeImpact of sarcopenia on outcomes following resection of pancreatic adenocarcinomaConditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent.Meta-analyses of treatment standards for pancreatic cancer.The association of adjuvant therapy with survival at the population level following pancreatic adenocarcinoma resection.dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational StudyPredictors of adjuvant treatment for pancreatic adenocarcinoma at the population level.Negative oncologic impact of poor postoperative pain control in left-sided pancreatic cancer.MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.Salirasib in the treatment of pancreatic cancer.Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
P2860
Q24186323-17695B29-8D1B-4B85-9BF5-977203216F96Q26746031-84D561E9-8660-4909-BCFB-07BA3C14D3E3Q26775916-685A979F-F3FE-405F-A9F6-12356D0311CDQ26787087-AE340538-2BC7-48A6-9894-6A5EFBB858F2Q26798674-9E0BEE11-F3C7-4CE6-AC54-7566DBE6F573Q26799425-392175B2-9117-4CE1-AE85-C0C57868300DQ28085711-01C101B1-4B49-435B-91EE-CFA8B59A411FQ28533753-75C427E4-F55A-4DBC-BDA0-A98BC10E1699Q33409382-5FA9AFC0-E955-4417-B89D-6C5DC36D926BQ33418870-E4E86E56-EADB-4D69-97EF-8449E98F92B4Q33559203-39FA86D4-00A0-4068-9052-6400E37C5657Q33699802-13251F37-C268-47A0-B0B8-417770249BF0Q33755147-5B1D033F-251A-40CE-AD73-B1F086D4C187Q33898080-4B6BC2AB-7641-4CE3-BD2A-FB7D3112004AQ33905392-F4812A63-AE2E-42AE-80DA-9307677C76C0Q33914671-F70E1103-A2C3-477F-B34B-40E1E35D76EEQ33989437-C4B8FDD0-A15C-428D-8F94-2AF34B31A91AQ33992146-F0C95634-FBFF-4D1F-981B-2CE361A97B26Q34129346-62FA3E33-897F-4B29-B04E-A65B056E0E44Q34405072-CD2140D1-F21E-4B95-98FD-46E2F26147AEQ34442914-20393B32-2D9D-468D-8B64-DA18E9D7F925Q34467156-67BD4E27-D26F-416D-9810-308366A2F8CBQ34827405-126069E9-241A-4ADF-8449-7125E7384546Q35803650-0E66D51C-2A02-44CB-864C-47454D1C86E2Q35890548-29465D3A-BBF9-42E8-ADA5-FEFBAD94B10DQ36224439-158EFBA6-A5E7-4024-8017-561BFE921D7FQ36281575-E465F5EB-8767-4043-B055-5D4A38865F02Q36310710-FCBBDDEB-1E9A-4E18-B518-D67228E86FA8Q36531542-8602F9D0-4BF5-495A-909B-9044870A29A4Q36544488-8496E9E3-090A-413A-AB76-0B3C3CC61AC8Q36626534-3FFBEE01-3FAB-4F84-8A60-A552F1BD0509Q36626623-C81C273D-056B-45EE-8B59-99BA50C177D1Q36640493-66BB9220-303F-4852-8825-79483B6DEA00Q36747432-C7227FB3-C57F-441A-AFBE-4DE627035C43Q37207004-CF6C0961-A1A5-4DFD-8FDB-D9AC13EC45C4Q37367887-3BE8A609-D0A9-4758-BB56-949B471C1D87Q37625229-23CF9615-D479-4F17-878E-C17AB8F24F78Q37642511-068BC88E-88F7-4F0A-A3E3-31F2225F15C1Q37763095-46958CDB-CD88-4757-A49C-F152C028A870Q37812010-1AD084CC-2562-4C6A-855B-B58CB59F614F
P2860
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A randomised phase III trial c ...... Therapy for Pancreatic Cancer.
@en
A randomised phase III trial c ...... Therapy for Pancreatic Cancer.
@nl
type
label
A randomised phase III trial c ...... Therapy for Pancreatic Cancer.
@en
A randomised phase III trial c ...... Therapy for Pancreatic Cancer.
@nl
prefLabel
A randomised phase III trial c ...... Therapy for Pancreatic Cancer.
@en
A randomised phase III trial c ...... Therapy for Pancreatic Cancer.
@nl
P2093
P2860
P356
P1476
A randomised phase III trial c ...... Therapy for Pancreatic Cancer
@en
P2093
J Yamamoto
K Kanemitsu
Y Matsuyama
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605256
P407
P577
2009-08-18T00:00:00Z